The use of COA in patient-centered drug development: part 1

Chad Gwaltney discusses the evolving importance of COAs in drug development, emphasizing a patient-centered approach. They explore the evolution of COA guidance documents, the importance of fit for purpose PRO instruments, and the evolving acceptance of quality of life measures in drug development. The conversation highlights the shift towards patient-centric evolution in drug development and the significance of incorporating patient perspectives in regulatory decisions.